(Q34663697)

English

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

scientific article

In more languages
default for all languages
No label defined

No description defined

Statements

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial (English)
Salah-Eddin Al-Batran
Christian Lerchenmüller
Werner Scheithauer
Heinz-Gert Höffkes
Sebastian Stintzing

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit